ShortHER trastuzumab treatment of HER2 breast cancer: 9 weeks v 1 year

Dr. Hamilton on the Optimal Duration of Trastuzumab in HER2+ Breast CancerПодробнее

ENHERTU Therapy: A Powerful New Cancer TreatmentПодробнее

How is HER2 positive breast cancer treated? #shortsПодробнее

HER2-Targeted TherapiesПодробнее

Adjuvant trastuzumab did not improve outcomes for patients with HER2-low breast cancerПодробнее

Unlocking the secrets of HER2+ve breast cancerПодробнее

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastasesПодробнее

Nine-weeks trastuzumab still effective compared with one year trastuzumab for early-stage HER2+ BCПодробнее

Study of Targeted Therapy for HER2-Positive Metastatic Breast CancerПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

# her 2 breast cancer # trastuzumabПодробнее

Optimizing Therapy in HER2+ Disease with Dr. Hope S. RugoПодробнее

Targeted Therapies for Breast Cancer: A Breakthrough in TreatmentПодробнее

Treatment Options for HER2+ Breast Cancer: A Comprehensive GuideПодробнее

TILs and OS in HER2+ early breast cancer: 10-year updated analysis of the ShortHER trialПодробнее

Herceptin, Perjeta and Phesgo #breastcancer #her2positiveПодробнее

Get to know HER2-positive breast cancer and its targeted treatmentsПодробнее

Trastuzumab Deruxtecan: A Cancer Treatment Milestone by Dr. Chellapuram at Star HospitalsПодробнее

T-DM1 as part of our standard of care with residual HER 2+ diseaseПодробнее